<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03618550</url>
  </required_header>
  <id_info>
    <org_study_id>18-160</org_study_id>
    <nct_id>NCT03618550</nct_id>
  </id_info>
  <brief_title>Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma</brief_title>
  <official_title>Phase II Study of Second-line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test any good and bad effects of the study drug,&#xD;
      pembrolizumab, in combination with GVD in the treatment of Hodgkin lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a phase II study evaluating pembrolizumab plus gemcitabine, vinorelbine, liposomal doxorubicin (GVD) in transplant eligible patients with relapsed or refractory Hodgkin lymphoma following failure of 1-line of multi-agent chemotherapy.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete response rate</measure>
    <time_frame>2 years</time_frame>
    <description>Response to pembrolizumab-GVD will be assessed using the RECIL criteria.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Relapsed or Refractory Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>pembrolizumab plus GVD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1: Patients will receive 2-4 cycles of pembrolizumab plus GVD&#xD;
Part 2: an additional 25 patients will be enrolled onto an expansion cohort. On the expansion, patients who achieve CR to 4 cycles of pembro-GVD will receive 13 cycles of pembrolizumab maintenance (instead of HDT/ASCT).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pembrolizumab</intervention_name>
    <description>Age 10-17: 2mg/kg (cap at 200mg), Age ≥ 18: 200 mg (flat) ,Day 1 of each 3 week cycle IV infusion 2-4 cycles (pre-ASCT)</description>
    <arm_group_label>pembrolizumab plus GVD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <description>1000mg/m^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles</description>
    <arm_group_label>pembrolizumab plus GVD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine</intervention_name>
    <description>20mg/m^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles</description>
    <arm_group_label>pembrolizumab plus GVD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liposomal doxorubicin</intervention_name>
    <description>15mg/m^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles</description>
    <arm_group_label>pembrolizumab plus GVD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem cell mobilization and collection</intervention_name>
    <description>Stem cell mobilization and collection will be performed as per standard MSKCC guidelines after 2-4 cycles of pembrolizumab-GVD.</description>
    <arm_group_label>pembrolizumab plus GVD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic diagnosis of classical Hodgkin's lymphoma.&#xD;
&#xD;
          -  Primary refractory or relapsed disease proven by excisional or core needle biopsy at&#xD;
             enrolling institution.&#xD;
&#xD;
          -  Relapse or refractory disease following 1 line of multi-agent chemotherapy.&#xD;
&#xD;
          -  Be willing and able to provide written informed consent/assent for the trial.&#xD;
&#xD;
          -  Be ≥ 18 years of age on day of signing informed consent.&#xD;
&#xD;
          -  Have measurable disease based on Lugano 2014 criteria&#xD;
&#xD;
          -  Have a performance status of 0 or 1 on the ECOG Performance Scale.&#xD;
&#xD;
          -  Demonstrate adequate organ function as defined in table below.&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) ≥1000 /mcL&#xD;
&#xD;
          -  Platelets ≥50,000 / mcL&#xD;
&#xD;
          -  Hemoglobin ≥8 g/dL&#xD;
&#xD;
          -  Serum creatinine OR ≤1.5 X upper limit of normal (ULN) OR&#xD;
&#xD;
          -  Measured or calculateda creatinine clearance (GFR can also be used in place of&#xD;
             creatinine or CrCl) ≥60 mL/min for subject with creatinine levels &gt; 1.5 X&#xD;
             institutional ULN&#xD;
&#xD;
          -  Serum total bilirubin ≤ 1.5 X ULN OR ≤ 3 X ULN for subjects with liver metastases&#xD;
&#xD;
          -  AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN OR ≤ 5 X ULN for subjects with liver metastases&#xD;
&#xD;
          -  Hemoglobin-adjusted diffusing capacity for carbon monoxide ≥50% (If unadjusted DLCO is&#xD;
             &gt;/= 50% then there is no need to calculate adjusted)&#xD;
&#xD;
          -  Ejection fraction ≥45%&#xD;
&#xD;
          -  Female subject of childbearing potential should have a negative urine or serum&#xD;
             pregnancy within 72 hours prior to receiving the first dose of study medication.&#xD;
&#xD;
          -  Female subjects of childbearing potential must be willing to use an adequate method of&#xD;
             contraception&#xD;
&#xD;
          -  Male subjects of childbearing potential must agree to use an adequate method of&#xD;
             contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received more than 1 prior treatment (combined modality therapy represents 1&#xD;
             treatment) for Hodgkin Lymphoma&#xD;
&#xD;
          -  Known pregnancy or breast-feeding.&#xD;
&#xD;
          -  Medical illness unrelated to Hodgkin's Lymphoma, which, in the opinion of the&#xD;
             attending physician and/or principal investigator, makes participation in this study&#xD;
             inappropriate.&#xD;
&#xD;
          -  Has received prior radiotherapy within 2 weeks of start of study treatment.&#xD;
             Participants must have recovered from all radiation-related toxicities, not require&#xD;
             corticosteroids, and not have had radiation pneumonitis.&#xD;
&#xD;
          -  Has known active central nervous system (CNS) metastases and/or carcinomatous&#xD;
             meningitis.&#xD;
&#xD;
          -  Has active autoimmune disease that has required systemic treatment in the past 2 years&#xD;
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive&#xD;
             drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid&#xD;
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a&#xD;
             form of systemic treatment.&#xD;
&#xD;
          -  Has known active HIV, Hepatitis B (e.g., Hepatitis B PCR positive) or Hepatitis C&#xD;
             (e.g., HCV RNA [qualitative] is detected).&#xD;
&#xD;
          -  Has received a live vaccine or live-attenuated vaccine within 30 days prior to the&#xD;
             first dose of study drug. Administration of killed vaccines is allowed.&#xD;
&#xD;
          -  Has a history of (non-infectious) pneumonitis that required steroids or has current&#xD;
             pneumonitis.&#xD;
&#xD;
          -  Has an active infection requiring systemic therapy.&#xD;
&#xD;
          -  Has undergone solid organ transplant at any time, or prior allogeneic hematopoietic&#xD;
             stem cell transplantation within the last 5 years. (Subjects who have had an&#xD;
             allogeneic hematopoietic transplant greater than 5 years ago are eligible as long as&#xD;
             there are no symptoms of GVHD.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alison Moskowitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alison Moskowitz, MD</last_name>
    <phone>212-639-4839</phone>
    <email>moskowia@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heiko Schoder, MD</last_name>
    <phone>212-639-2079</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Moskowitz, MD</last_name>
      <phone>305-243-5302</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Moskowitz, MD</last_name>
      <phone>212-639-4839</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Moskowitz, MD</last_name>
      <phone>212-639-4839</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Moskowitz, MD</last_name>
      <phone>212-639-4839</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center @ Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Moskowitz, MD</last_name>
      <phone>212-639-4839</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Moskowitz, MD</last_name>
      <phone>212-639-4839</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan - Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Moskowitz, MD</last_name>
      <phone>212-639-4839</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Moskowitz, MD</last_name>
      <phone>212-639-4839</phone>
    </contact>
    <contact_backup>
      <last_name>Heiko Schoder, MD</last_name>
      <phone>212-639-2079</phone>
    </contact_backup>
    <investigator>
      <last_name>Alison Moskowitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Moskowitz, MD</last_name>
      <phone>212-639-4839</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 30, 2018</study_first_submitted>
  <study_first_submitted_qc>August 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2018</study_first_posted>
  <last_update_submitted>June 23, 2021</last_update_submitted>
  <last_update_submitted_qc>June 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pembrolizumab</keyword>
  <keyword>GVD</keyword>
  <keyword>18-160</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

